A Decrease in Maternal Plasma Concentrations of SVEGFR-2 Precedes the Clinical Diagnosis of Preeclampsia

Overview

Journal Am J Obstet Gynecol

Publisher Elsevier

Specialty Gynecology & Obstetrics

Date 2010 Jun 1

PMID 20510958

Citations 21

Authors

Tinnakorn Chaiworapongsa

Roberto Romero

Adi L Tarca

Juan Pedro Kusanovic

Francesca Gotsch

Pooja Mittal

Sun Kwon Kim

Edi Vaisbuch

Shali Mazaki-Tovi

Offer Erez

Zhong Dong

Chong Jai Kim

Lami Yeo

Sonia S Hassan

Affiliations

Soon will be listed here.

Abstract

Objective: The aim of this study was to examine if maternal plasma concentrations of soluble vascular endothelial growth factor receptor (sVEGFR)-2 change prior to the diagnosis of preeclampsia.

Study Design: A longitudinal study was conducted in normal pregnant women (n = 160) and patients with preeclampsia (n = 40). Blood samples were collected at 7 gestational age intervals from 6 weeks to term. Plasma concentrations of sVEGFR-2 were determined by enzyme-linked immunosorbent assay. Analysis was performed with cross-sectional and longitudinal (mixed effects model) approaches.

Results: Mothers destined to develop preeclampsia have lower plasma sVEGFR-2 concentrations than those who will have a normal pregnancy (longitudinal approach; P < .05). Cross-sectional analysis suggested that the median plasma sVEGFR-2 concentration in women destined to develop preeclampsia was significantly lower than that in normal pregnant women from 28-31 weeks of gestation (P = .001) or 6-10 weeks prior to the diagnosis (P < .001).

Conclusion: A lower maternal plasma sVEGFR-2 concentration precedes the development of preeclampsia, both term and preterm.

Citing Articles

Dymara-Konopka W, Laskowska M, Grywalska E, Hymos A, Blazewicz A, Leszczynska-Gorzelak B Int J Mol Sci. 2023; 24(2).

PMID: 36674486 PMC: 9864962. DOI: 10.3390/ijms24020972.

Prediction of preeclampsia throughout gestation with maternal characteristics and biophysical and biochemical markers: a longitudinal study.

Tarca A, Taran A, Romero R, Jung E, Paredes C, Bhatti G Am J Obstet Gynecol. 2022; 226(1):126.e1-126.e22.

PMID: 34998477 PMC: 8749051. DOI: 10.1016/j.ajog.2021.01.020.

The profiles of soluble adhesion molecules in the "great obstetrical syndromes".

Docheva N, Romero R, Chaemsaithong P, Tarca A, Bhatti G, Pacora P J Matern Fetal Neonatal Med. 2018; 32(13):2113-2136.

PMID: 29320948 PMC: 6070437. DOI: 10.1080/14767058.2018.1427058.

Role of Extracellular Vesicles and microRNAs on Dysfunctional Angiogenesis during Preeclamptic Pregnancies.

Escudero C, Herlitz K, Troncoso F, Acurio J, Aguayo C, Roberts J Front Physiol. 2016; 7:98.

PMID: 27047385 PMC: 4796029. DOI: 10.3389/fphys.2016.00098.

Maternal plasma angiogenic index-1 (placental growth factor/soluble vascular endothelial growth factor receptor-1) is a biomarker for the burden of placental lesions consistent with uteroplacental underperfusion: a longitudinal case-cohort study.

Korzeniewski S, Romero R, Chaiworapongsa T, Chaemsaithong P, Kim C, Kim Y Am J Obstet Gynecol. 2015; 214(5):629.e1-629.e17.

PMID: 26688491 PMC: 5769706. DOI: 10.1016/j.ajog.2015.11.015.

References

Crispi F, Llurba E, Dominguez C, Martin-Gallan P, Cabero L, Gratacos E . Predictive value of angiogenic factors and uterine artery Doppler for early- versus late-onset pre-eclampsia and intrauterine growth restriction. Ultrasound Obstet Gynecol. 2007; 31(3):303-9. DOI: 10.1002/uog.5184. View

Venkatesha S, Toporsian M, Lam C, Hanai J, Mammoto T, Kim Y . Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med. 2006; 12(6):642-9. DOI: 10.1038/nm1429. View

Romero R, Nien J, Espinoza J, Todem D, Fu W, Chung H . A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a.... J Matern Fetal Neonatal Med. 2008; 21(1):9-23. PMC: 2587364. DOI: 10.1080/14767050701830480. View

DePrimo S, Bello C, Smeraglia J, Baum C, Spinella D, Rini B . Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins. J Transl Med. 2007; 5:32. PMC: 1939830. DOI: 10.1186/1479-5876-5-32. View

Stepan H . Angiogenic factors and pre-eclampsia: an early marker is needed. Clin Sci (Lond). 2008; 116(3):231-2. DOI: 10.1042/CS20080598. View

Becker C, Farnebo F, Iordanescu I, Behonick D, Shih M, Dunning P . Gene therapy of prostate cancer with the soluble vascular endothelial growth factor receptor Flk1. Cancer Biol Ther. 2002; 1(5):548-53. DOI: 10.4161/cbt.1.5.176. View

Erez O, Romero R, Espinoza J, Fu W, Todem D, Kusanovic J . The change in concentrations of angiogenic and anti-angiogenic factors in maternal plasma between the first and second trimesters in risk assessment for the subsequent development of preeclampsia and small-for-gestational age. J Matern Fetal Neonatal Med. 2008; 21(5):279-87. PMC: 2846114. DOI: 10.1080/14767050802034545. View

Kupferminc M, Daniel Y, Englender T, Baram A, Many A, Jaffa A . Vascular endothelial growth factor is increased in patients with preeclampsia. Am J Reprod Immunol. 1997; 38(4):302-6. DOI: 10.1111/j.1600-0897.1997.tb00519.x. View

Ebos J, Lee C, Bogdanovic E, Alami J, van Slyke P, Francia G . Vascular endothelial growth factor-mediated decrease in plasma soluble vascular endothelial growth factor receptor-2 levels as a surrogate biomarker for tumor growth. Cancer Res. 2008; 68(2):521-9. DOI: 10.1158/0008-5472.CAN-07-3217. View

10.

Roberts J, Gammill H . Preeclampsia: recent insights. Hypertension. 2005; 46(6):1243-9. DOI: 10.1161/01.HYP.0000188408.49896.c5. View

11.

Ebos J, Lee C, Christensen J, Mutsaers A, Kerbel R . Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy. Proc Natl Acad Sci U S A. 2007; 104(43):17069-74. PMC: 2040401. DOI: 10.1073/pnas.0708148104. View

12.

Levine R, Maynard S, Qian C, Lim K, England L, Yu K . Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med. 2004; 350(7):672-83. DOI: 10.1056/NEJMoa031884. View

13.

Aref S, El Sherbiny M, Goda T, Fouda M, Al Askalany H, Abdalla D . Soluble VEGF/sFLt1 ratio is an independent predictor of AML patient out come. Hematology. 2005; 10(2):131-4. DOI: 10.1080/10245330500065797. View

14.

von Dadelszen P, Magee L, Roberts J . Subclassification of preeclampsia. Hypertens Pregnancy. 2003; 22(2):143-8. DOI: 10.1081/PRG-120021060. View

15.

Sharkey A, Cooper J, Balmforth J, McLaren J, Clark D, Charnock-Jones D . Maternal plasma levels of vascular endothelial growth factor in normotensive pregnancies and in pregnancies complicated by pre-eclampsia. Eur J Clin Invest. 1996; 26(12):1182-5. DOI: 10.1046/j.1365-2362.1996.830605.x. View

16.

Alexander G, Himes J, Kaufman R, Mor J, Kogan M . A United States national reference for fetal growth. Obstet Gynecol. 1996; 87(2):163-8. DOI: 10.1016/0029-7844(95)00386-X. View

17.

Sibai B . Hypertensive disorders of pregnancy: the United States perspective. Curr Opin Obstet Gynecol. 2008; 20(2):102-6. DOI: 10.1097/GCO.0b013e3282f73380. View

18.

Sibai B, Ewell M, LEVINE R, Klebanoff M, Esterlitz J, Catalano P . Risk factors associated with preeclampsia in healthy nulliparous women. The Calcium for Preeclampsia Prevention (CPEP) Study Group. Am J Obstet Gynecol. 1997; 177(5):1003-10. DOI: 10.1016/s0002-9378(97)70004-8. View

19.

Sibai B, Koch M, Freire S, Silva J, Rudge M, Martins-Costa S . Serum inhibin A and angiogenic factor levels in pregnancies with previous preeclampsia and/or chronic hypertension: are they useful markers for prediction of subsequent preeclampsia?. Am J Obstet Gynecol. 2008; 199(3):268.e1-9. DOI: 10.1016/j.ajog.2008.06.071. View

20.

Haddad R, Romero R, Gould B, Tromp G, Gotsch F, Edwin S . Angiogenesis gene expression in mouse uterus during the common pathway of parturition. Am J Obstet Gynecol. 2008; 198(5):539.e1-8. DOI: 10.1016/j.ajog.2007.11.021. View